# A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

> **NCT01132690** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 11 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Taliglucerase alfa

## Key facts

- **NCT ID:** NCT01132690
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132690, "A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01132690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*